Our Mission
Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer - condition that is likely to affect 1 in 8 men at some stage of their lives.
Cambridge Oncometrix is developing a non-invasive test that will allow men to check the health of their prostate regularly.
This test will be capable of accurately detecting prostate cancer at the early stages of its development.
Current status
1
2
3
Biomarker discovery & validation
Identify key-biomarkers
Develop assay
Biomarker transition from
laboratory to clinical studies
Perform proof-of-concept clinical study in target population
Refine assay, develop test instrumentation
Qualify biomarkers in a large clinical trial
Delivery to the public
Obtain regulatory approvals
Deliver tests and services